Eli Lilly (LLY) is solidifying its leadership in the burgeoning weight loss drug market, currently holding a 60% share in the U.S. with its products, Mounjaro and Zepbound. The company has seen triple-digit revenue growth as it capitalizes on the demand for GLP-1 drugs, following its entry into the market shortly after Novo Nordisk. With its oral weight loss candidate under regulatory review, Lilly is poised for further expansion, especially as it outperformed Novo’s offerings in head-to-head studies.
Meanwhile, Viking Therapeutics (VKTX) is making strides with its candidate VK2735, currently in phase 2 and phase 3 trials. The drug shows promise in appetite control and blood sugar management, potentially positioning Viking as a competitive player if it secures regulatory approval. Given the high demand for weight loss drugs, Viking could carve out a significant market share.
For investors, both Lilly and Viking present compelling opportunities, but Lilly’s established market presence and upcoming regulatory decisions could provide immediate growth potential. For a deeper dive into this dynamic sector, I recommend checking out the full article.
Source: fool.com